Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 4/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 4/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.40 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25303177 | 0.92 | AKR1C1 (0.52) | AKR1C1HDAC4AKR1C3AKR1C2CES2 | |
| SCHEMBL28679746 | 0.87 | ALDH1A1 (0.45) | AKR1C1HDAC4APPCYP2C19CYP2C9 | |
| SCHEMBL20242254 | 0.87 | HDAC4 (0.60) | AKR1C1HDAC4AKR1C3AKR1C2APP | |
| SCHEMBL20249843 | 0.87 | HDAC4 (0.60) | AKR1C1HDAC4AKR1C3AKR1C2CES2 | |
| SCHEMBL31445382 | 0.82 | AKR1C3 (0.36) | AKR1C1HDAC4AKR1C3AKR1C2APP | |
| SCHEMBL3860372 | 0.81 | HDAC4 (0.42) | HDAC4CES2CES1ALB | |
| SCHEMBL20242085 | 0.80 | HDAC4 (0.61) | AKR1C1HDAC4AKR1C3AKR1C2CES2 | |
| SCHEMBL3373867 | 0.80 | HDAC4 (0.70) | AKR1C1HDAC4AKR1C3AKR1C2APP | |
| SCHEMBL31125559 | 0.79 | HDAC4 (0.59) | AKR1C1HDAC4AKR1C3AKR1C2APP | |
| SCHEMBL301133 | 0.79 | HDAC4 (0.59) | AKR1C1HDAC4AKR1C3AKR1C2APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113861072-A | Preparation method of aryl cyclopropane compound | 上海麦克林生化科技有限公司 | 2021-12-31 | — | — | CN | disclosed |
| US-20180251431-A1 | 1,3-SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACID LEVELS | VERTEX PHARMACEUTICALS INCORPORATED | 2018-09-06 | — | — | US | disclosed |
| WO-2018107056-A1 | 1,3-SUBSTITUED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACIC LEVELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-06-14 | — | — | WO | disclosed |
| EP-0459285-B1 | Ortho-substituted benzyl esters of cyclopropane carboxylic acids | BASF AG (DE) | 1994-12-14 | — | — | EP | disclosed |
| US-5371268-A | Ortho-substituted benzyl esters of cyclopropanecarboxylic acids | BASF AKTIENGESELLSCHAFT (DE) | 1994-12-06 | — | — | US | disclosed |
| EP-0459285-A1 | Ortho-substituted benzyl esters of cyclopropane carboxylic acids | BASF Aktiengesellschaft (DE) | 1991-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251431-A1 | 1,3-SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACID LEVELS | HSD17B4, CPT1A, ADH1A | AKR1C1 19/4885HDAC4 2184/4885AKR1C3 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.